Menu
Search
|

Menu

Close
X

Zealand Pharma A/S ZEAL.OQ (NASDAQ Stock Exchange Global Select Market)

16.52 USD
+1.06 (+6.86%)
As of Feb 23
chart
Previous Close 15.46
Open 15.88
Volume 5,404
3m Avg Volume 5,616
Today’s High 16.52
Today’s Low 15.77
52 Week High 20.35
52 Week Low 12.32
Shares Outstanding (mil) 30.75
Market Capitalization (mil) 3,751.36
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
2.00 Mean rating from 9 analysts

KEY STATS

Revenue (mm, DKK)
FY17
129
FY16
235
FY15
188
EPS (DKK)
FY17
-6.171
FY16
-6.746
FY15
-5.305
*Note: Units in Millions of Danish Krone
**Note: Units in Danish Krone

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
32.90
Price to Sales (TTM)
vs sector
12.16
5.77
Price to Book (MRQ)
vs sector
17.22
5.41
Price to Cash Flow (TTM)
vs sector
148.70
23.42
Total Debt to Equity (MRQ)
vs sector
80.46
16.52
LT Debt to Equity (MRQ)
vs sector
78.44
12.22
Return on Investment (TTM)
vs sector
-26.95
14.43
Return on Equity (TTM)
vs sector
-67.92
16.13

EXECUTIVE LEADERSHIP

Alf Nicklasson
Independent Chairman of the Board, Since 2015
Salary: --
Bonus: --
Britt Meelby Jensen
President, Chief Executive Officer, Member of the Executive Management, Since 2015
Salary: kr.3,795,000.00
Bonus: kr.683,000.00
Rosemary Crane
Independent Vice Chairman of the Board, Since 2015
Salary: --
Bonus: --
Mats Blom
Chief Financial Officer, Senior Vice President, Member of the Executive Management, Since 2016
Salary: kr.2,448,000.00
Bonus: kr.526,000.00
Andrew Parker
Senior Vice President, Chief Scientific Officer, Since 2016
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

Smedeland 36
GLOSTRUP     2600

Phone:

Zealand Pharma A/S is a Denmark-based biopharmaceutical company engaged in the discovery, development and commercialization of peptide-based medicines. The Company's pipeline comprises two implementation areas: Cardio-metabolic diseases and Other indications. The Cardio-metabolic diseases area includes medicines for diabetes and obesity treatment, such as Lyxumia (Lixisenatide), Lyxumia/Lantus, ZP2929 and Danegaptide. The Other indications area offers ZP1848, Elsiglutide and ZP1480 (ABT-719) drugs for inflammatory bowel disease, chemotherapy-induced diarrhea and acute kidney injury treatment. Furthermore, the Company collaborates with a number of partners, such as Sanofi, Helsinn, Boehringer Ingelheim, Abbvie and Eli Lilly.

SPONSORED STORIES